Uncovering the true cost of your pharmacy benefit
TRANSPARENT SAVINGS
Consistently delivering low PMPM
*Than national benchmarks
COMPREHENSIVE STRATEGY
Employing multiple drug management methods
The most effective PBMs help deliver the best patient outcomes at a lower cost. Prime takes a holistic approach to help ensure our formularies include the best options, promote evidence-based biosimilars and offer industry-leading utilization programs.
Formulary management
Some PBMs prioritize high-priced drugs over lower-cost options due to manufacturer rebates. But Prime focuses on the lowest-cost, most clinically effective options to keep costs low and improve health outcomes.
Specialty drug management
Prime is focused on improving access to low-cost specialty drugs by developing innovative products and driving the use of evidence-based biosimilars.
Utilization management (UM)
We help our clients choose UM programs that not only provide their members safe, cost-effective medicines, but also address industry-wide problems like inappropriate use and fraud, waste and abuse.
Related news
Perspectives
May 1, 2024
Prime Therapeutics releases new clinical insights report, “Weight management: A holistic journey”
Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss
Perspectives
April 30, 2024
AMCP 2024: Behind the GLP-1 Spotlight Session with Ben Urick
Urick, senior principal health outcomes researcher, shares more about his Spotlight Session at the Academy of Managed Care Pharmacy (AMCP)’s Annual Meeting
Perspectives
April 30, 2024
Quarterly Drug Pipeline
Clinical insights and competitive intelligence on anticipated drugs in development
1 Milliman survey, 2020; commercial business including fully insured and self-insured
2 Prime Therapeutics internal data, 2017; savings based on actual savings reports, inclusive of all formulary savings
3 U.S. Food and Drug Administration, and Federal Trade Commission. (2020, February 3). FDA and FTC announce new efforts to further deter anti-competitive business practices, support competitive market for biological products to help Americans [Press release]. https://www.fda.gov/news-events/press-announcements/fda-and-ftc-announce-new-efforts-further-deter-anti-competitive-business-practices-support
4 Watanabe, J. H., McInnis, T., & Hirsch, J. D. (2018, March 26). Cost of prescription drug-related morbidity and mortality. Annals of Pharmacotherapy, 52(9). https://journals.sagepub.com/doi/10.1177/1060028018765159